chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain, Vaccination site pain
Clinical narrative: Bad headache; Chills; Body aches; Tiredness; Arm sore at injection site; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200), via an unspecified route of administration in the left arm on 12Feb2021 at 14:30 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Medical history included allergic to LEXAPRO. Concomitant medications included sertraline (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN), selenium sulphide (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 13Feb2021 at 03:30, the patient experienced bad headache, chills, body aches, tiredness and arm sore at the injection site. The patient did not receive any treatment for the events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events bad headache, chills, body aches, tiredness and arm sore at the injection site were resolved on an unspecified date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site erythema, Vaccination site pain, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Redness at the injection site; Swelling at the injection site; Soreness at injection site; Itchiness at injection site; Left side neck (muscle) pain; This is a spontaneous report received from a contactable consumer, the patient. A 68-years-old adult non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206), via an unspecified route of administration in left arm on 11Mar2021, at 14:30 (at the age of 68-years-old) as a single dose, for COVID-19 immunisation. Medical history included breast cancer survivor and rheumatoid arthritis. Concomitant medications included letrazole (MANUFACTURER UNKNOWN), methotrexate (MANUFACTURER UNKNOWN) and losartan (MANUFACTURER UNKNOWN), all for an unknown indication and taken within two weeks of vaccination and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200), via an unspecified route of administration in left arm on 18Feb2021 at 14:30 (at the age of 67-year-old) as a single dose, for COVID-19 immunisation. The patient had no known allergies to medications, food, or other products. The patient had not received any other vaccines within 4 weeks prior to COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 12Mar2021 at 9:00, the patient experienced redness, swelling, hot to touch, itchiness, soreness at injection site and left side neck (muscle) pain which resulted in doctor or other healthcare professional office or clinic visit. Therapeutic measures taken as a result of the events included Zyrtec tablet. The clinical outcome of events redness, swelling, hot to touch, itchiness, soreness at injection site and left side neck (muscle) pain was recovered on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Partial facial numbness near and around my left eye and cheek; This is a spontaneous report received from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: en6207) via an unspecified route of administration in right arm on 19Mar2021 at 11:15 (age at vaccination 41-years-old), as a single dose for COVID-19 immunisation. Medical history included seasonal allergies and gastroesophageal reflux disease (GERD). Concomitant medications included fexofenadine hydrochloride (ALLEGRA) and famotidine (MANUFACTURER UNKNOWN) both for unknown indication, from unknown date. The patient was allergic to amoxicillin. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 19Mar2021 at 15:00, the patient experienced partial facial numbness near and around her left eye and cheek. The adverse event did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported event numbness facial. The clinical outcome of the event numbness facial was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chills, Cough, Dizziness, Myalgia
Clinical narrative: Chest tightness; throat itching; light headed; coughing; chills; muscle aches; This is a spontaneous report received from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207), via an unspecified route of administration in the left arm on 19Mar2021 at 13:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, Hashimoto's disease, diabetes type 2 and hypertension. Concomitant medications included levothyroxine 125 mcg (MANUFACTURER UNKNOWN), spironolactone (MANUFACTURER UNKNOWN) and paroxetine (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received lisinopril (MANUFACTURER UNKNOWN) on an unknown date and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 19Marr2021 at 14:15, the patient experienced chest tightness, throat itching, light headed, coughing, chills and muscle aches. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events chest tightness, throat itching, light headed, coughing, chills and muscle aches. The clinical outcomes of the events chest tightness, throat itching, light headed, coughing, chills and muscle aches were not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Throat irritation
Clinical narrative: Chest tightness; throat itching; light headed; coughing; chills; muscle aches; This is a spontaneous report received from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207), via an unspecified route of administration in the left arm on 19Mar2021 at 13:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, Hashimoto's disease, diabetes type 2 and hypertension. Concomitant medications included levothyroxine 125 mcg (MANUFACTURER UNKNOWN), spironolactone (MANUFACTURER UNKNOWN) and paroxetine (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received lisinopril (MANUFACTURER UNKNOWN) on an unknown date and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 19Marr2021 at 14:15, the patient experienced chest tightness, throat itching, light headed, coughing, chills and muscle aches. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events chest tightness, throat itching, light headed, coughing, chills and muscle aches. The clinical outcomes of the events chest tightness, throat itching, light headed, coughing, chills and muscle aches were not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Arthralgia, Chills, Diarrhoea
Clinical narrative: cramps in stomach; chills; aches in joints; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 77-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route of administration in the left arm on 10Mar2021 at 08:45 (at the age of 77-year-old), as a single dose for COVID-19 immunisation. Medical history included osteoporosis, hypertension, restless legs and low thyroid. Concomitant medications included levetiractan (MANUFACTURER UNKNOWN), ropinirole (MANUFACTURER UNKNOWN), baby aspirin (MANUFACTURER UNKNOWN) and valsartan (MANUFACTURER UNKNOWN) taken within last two weeks of vaccination for an unknown indication from an unspecified date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had not tested positive for COVID-19 since the vaccination. On 18Mar2021 at 12:00 AM, the patient experienced chills, aches in joints, cramps in stomach, and diarrhoea. The patient did not receive any treatment for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events chills, aches in joints, cramps in stomach, and diarrhoea was recovering.   No follow-up attempts are possible. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Body temperature abnormal, Chills, Nausea, Tremor
Clinical narrative: nausea; Vomitting; 101 temperature; Chills; shakes; This is a spontaneous report from a contactable nurse, the patient. A 69-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 18Mar2021 at 11:00 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. The patients medical history included common variable immunodeficiency (CVID). The patient was allergic to dairy, sugar, hops, mushrooms, sesame, spinach, turkey, whole wheat and yeast). Concomitant medications included baclofen (MANUFACTURER UNKNOWN) 10 milligram (mg) and D2 ergocalciferol (MANUFACTURER UNKNOWN) 50,000 units. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. On 20Mar2021 at 05:00, the patient experienced nausea, vomiting, 101 temperature, chills and shakes. No treatment was received for these events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of nausea, vomiting, 101 temperature, chills and shakes was recovering at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: nausea; Vomitting; 101 temperature; Chills; shakes; This is a spontaneous report from a contactable nurse, the patient. A 69-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 18Mar2021 at 11:00 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. The patients medical history included common variable immunodeficiency (CVID). The patient was allergic to dairy, sugar, hops, mushrooms, sesame, spinach, turkey, whole wheat and yeast). Concomitant medications included baclofen (MANUFACTURER UNKNOWN) 10 milligram (mg) and D2 ergocalciferol (MANUFACTURER UNKNOWN) 50,000 units. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. On 20Mar2021 at 05:00, the patient experienced nausea, vomiting, 101 temperature, chills and shakes. No treatment was received for these events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of nausea, vomiting, 101 temperature, chills and shakes was recovering at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Blood pressure increased, Blood pressure measurement, Cough, Headache
Clinical narrative: Increased BP; 10 days after shot had neck pain; Teeth & jaw hurt; Cough; jaw hurt; Congestion; 10 days after shot had muscle pain; 10 days after shot had joint pain; Headache; Same day of shot sore arm & achy.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208) via an unspecified route of administration in the left arm on 10Mar2021 at 09:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The patient medical history included neuropathy, very frequent premature ventricular contractions (PVC's), severe arthritis, high blood pressure, degenerative disc disease and bulging discs. The patient had a history of drug allergy to codeine, steroids, ultram, augmentin, cipro, doxycycline and sulphur antibiotics. The concomitant medications included SYNTHROID, diltiazem (MANUFACTURER UNKNOWN), flecainide (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and ibup(ibuprofen) (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. On 10Mar2021, (same day of shot) the patient experienced sore arm and achy. The patient felt better after 2 days, but 10 days after the shot on 19Mar2021at 22:00, the patient experienced muscle, neck, joint pain, headache, teeth and jaw hurt, cough, congestion and increased blood pressure (BP). No therapeutic measures were taken as a result of adverse events. The clinical outcome of the event pain in arm was recovering and the clinical outcome of the events muscle pain, neck pain, joint pain, headache, toothache and jaw pain, cough, congestion nasal, blood pressure increased was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nasal congestion, Neck pain, Pain in extremity, Pain in jaw
Clinical narrative: Increased BP; 10 days after shot had neck pain; Teeth & jaw hurt; Cough; jaw hurt; Congestion; 10 days after shot had muscle pain; 10 days after shot had joint pain; Headache; Same day of shot sore arm & achy.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208) via an unspecified route of administration in the left arm on 10Mar2021 at 09:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The patient medical history included neuropathy, very frequent premature ventricular contractions (PVC's), severe arthritis, high blood pressure, degenerative disc disease and bulging discs. The patient had a history of drug allergy to codeine, steroids, ultram, augmentin, cipro, doxycycline and sulphur antibiotics. The concomitant medications included SYNTHROID, diltiazem (MANUFACTURER UNKNOWN), flecainide (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and ibup(ibuprofen) (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. On 10Mar2021, (same day of shot) the patient experienced sore arm and achy. The patient felt better after 2 days, but 10 days after the shot on 19Mar2021at 22:00, the patient experienced muscle, neck, joint pain, headache, teeth and jaw hurt, cough, congestion and increased blood pressure (BP). No therapeutic measures were taken as a result of adverse events. The clinical outcome of the event pain in arm was recovering and the clinical outcome of the events muscle pain, neck pain, joint pain, headache, toothache and jaw pain, cough, congestion nasal, blood pressure increased was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Toothache
Clinical narrative: Increased BP; 10 days after shot had neck pain; Teeth & jaw hurt; Cough; jaw hurt; Congestion; 10 days after shot had muscle pain; 10 days after shot had joint pain; Headache; Same day of shot sore arm & achy.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208) via an unspecified route of administration in the left arm on 10Mar2021 at 09:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The patient medical history included neuropathy, very frequent premature ventricular contractions (PVC's), severe arthritis, high blood pressure, degenerative disc disease and bulging discs. The patient had a history of drug allergy to codeine, steroids, ultram, augmentin, cipro, doxycycline and sulphur antibiotics. The concomitant medications included SYNTHROID, diltiazem (MANUFACTURER UNKNOWN), flecainide (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and ibup(ibuprofen) (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. On 10Mar2021, (same day of shot) the patient experienced sore arm and achy. The patient felt better after 2 days, but 10 days after the shot on 19Mar2021at 22:00, the patient experienced muscle, neck, joint pain, headache, teeth and jaw hurt, cough, congestion and increased blood pressure (BP). No therapeutic measures were taken as a result of adverse events. The clinical outcome of the event pain in arm was recovering and the clinical outcome of the events muscle pain, neck pain, joint pain, headache, toothache and jaw pain, cough, congestion nasal, blood pressure increased was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash erythematous
Clinical narrative: Small red bumpy rash like patch on the inside of right wrist; Small red bumpy rash like patch on the inside of right wrist; This is a spontaneous report received from a contactable consumer, the patient. A 16-year-old non pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via unspecified route of administration in the left arm on 09Mar2021 at 10:45 (at the age of 16-year-old) as single dose for COVID-19 immunisation. Medical history included downs syndrome and hypothyroid. The patient did not have any allergies to medications, food, or other products. Concomitant medications included digestive enzymes (unspecified) and levothyroxine (MANUFACTURER UNKNOWN) received on unspecified date for unknown indication and unknown if ongoing. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.  On 17Mar2021, the patient developed a small, red, bumpy, rash-like patch, approximately two inches by one inch, on the inside of her right wrist, eight days after the shot. Therapeutic measures were taken as a result of adverse event with antibiotic ointment, covered the area . The clinical outcome of small red bumpy rash like patch was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Lip swelling, Swelling face
Clinical narrative: Swollen Cheek; Swollen lips; This is a spontaneous report received from a contactable consumer, the patient. A 77-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EL3249), via an unspecified route of administration in the left arm on 25Jan2021 at 12:15 (at the age of 77-years-old), as a single dose for COVID-19 immunisation. The patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6200), via an unspecified route of administration in the left arm on 15Feb2021 at 15:15 (at the age of 77-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. The patient did not receive any other medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27Jan2021 at 09:00 (after receiving the first dose of COVID-19 vaccination), the patient experienced swollen cheek and lip. On an unknown date 2 weeks and 4 weeks, (after second dose of COVID-19 vaccination) the patient experienced swollen cheek and lip. The events resulted in doctor or other healthcare professional office/clinic visit. The patient was treated with prednisone and anti-histamine for the events. The clinical outcome of the events swollen cheek and lip was resolved on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Dizziness, Fatigue, Headache, Oropharyngeal pain
Clinical narrative: Fever; severe headache; body aches; sore throat; cough; severe fatigue; dizziness; This is a spontaneous report received from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration on 19Mar2021 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included postural orthostatic tachycardia syndrome (POTS). Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had history of allergy to ibuprofen and amoxicillin. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications were not reported. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration on 26Feb2021 as a single dose for COVID-19 immunisation within four weeks prior to the second dose. On 19Mar2021, the patient had experienced fever, severe headache, body aches, sore throat, cough, severe fatigue and dizziness. The patient did not receive treatment for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, severe headache, body aches, sore throat, cough, severe fatigue and dizziness was resolving.    No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Fever; severe headache; body aches; sore throat; cough; severe fatigue; dizziness; This is a spontaneous report received from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration on 19Mar2021 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included postural orthostatic tachycardia syndrome (POTS). Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had history of allergy to ibuprofen and amoxicillin. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications were not reported. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration on 26Feb2021 as a single dose for COVID-19 immunisation within four weeks prior to the second dose. On 19Mar2021, the patient had experienced fever, severe headache, body aches, sore throat, cough, severe fatigue and dizziness. The patient did not receive treatment for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, severe headache, body aches, sore throat, cough, severe fatigue and dizziness was resolving.    No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Hypersensitivity, Pain, Swelling
Clinical narrative: very painful; swollen; big red; This is a spontaneous report received from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206) via an unspecified route of administration in the left arm on 10Mar2021 at 13:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included mild intermittent asthma. The patient had PEG and poly sorbate allergy test and the result found to be negative after the reaction to dose 1 in unknown date in 2021. Concomitant medication included vitamin d (MANUFACTURER UNKNOWN), Multi vitamin (MANUFACTURER UNKNOWN), Omega 3 (MANUFACTURER UNKNOWN), ALLEGRA, iron (MANUFACTURER UNKNOWN), Probiotic (MANUFACTURER UNKNOWN) for unknown indication. The patient had a history of sensitivity to erythromycin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient received vaccine on Wednesday, on Friday night, on 12Mar2021 at 21:45, the patient experienced a big red, mottled, swollen, hot circle, which was very painful but not itchy. The patients dark place remained and was crackling on dermal surface. Her pain subsided 5 full days out and dark patch was remained at the time of report. Therapeutic measures was taken as results of events and included the treatment with tylenol and applied cold compress. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events swelling, redness and pain was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Migraine, Vaccination site pain
Clinical narrative: The headache was (relative to a migraine) mild, and somewhat intermittent, but is combined with brain fog.; Fatigue; Felt a little washed out.; Slight pain at injection site for a few days; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old adult non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203), via an unspecified route of administration in the left arm on 13Mar2021 at 14:45 (at the age of 69-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included Acyclovir (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN), probiotic (MANUFACTURER UNKNOWN), lutein (MANUFACTURER UNKNOWN), all for unspecified indication and from unspecified date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: E19266), via an unspecified route of administration in the left arm on 20Feb2021 at 17:45, as a single dose for COVID-19 immunisation. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. On 14Mar2021, at 5:00 the patient felt a little washed out, slight pain at injection site for a few days, all these symptoms were still continuing by 20Mar2021 (Saturday) and on an unknown date, patient experienced fatigue and headache which was relative to a migraine, mild, and somewhat intermittent but was combined with brain fog. No therapeutic measures were taken as a result of the events. The clinical outcome of the event washed out, pain at injection site, fatigue and migraine headache was not recovered. No follow-up attempts are possible. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Myalgia, Pain in extremity, Peripheral swelling
Clinical narrative: Chills; Headache; Muscles hurt; Face swollen; Hands swollen; It hurts to walk; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via unspecified route of administration in left arm on 19Mar2021 at 09:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. It was reported that the patient had no known allergies. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications (unspecified) were taken within two weeks of vaccination. On 19Mar2021 at 22:00, the patient experienced chills, headache, muscles hurt, hands and face swollen and hurts to walk. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events chills, headache, muscles hurt, hands and face swollen and hurts to walk were not recovered at the time of this report.   Information about lot number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling face
Clinical narrative: Chills; Headache; Muscles hurt; Face swollen; Hands swollen; It hurts to walk; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via unspecified route of administration in left arm on 19Mar2021 at 09:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. It was reported that the patient had no known allergies. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications (unspecified) were taken within two weeks of vaccination. On 19Mar2021 at 22:00, the patient experienced chills, headache, muscles hurt, hands and face swollen and hurts to walk. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events chills, headache, muscles hurt, hands and face swollen and hurts to walk were not recovered at the time of this report.   Information about lot number cannot be obtained. No further information is expected.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Palpitations
Clinical narrative: Heart palpations started about 5 days after 2nd dose.; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN3200) via unspecified route of administration in the left arm on 16Feb2021 at 16:00 (at the age of 73-year-old), as a single dose for COVID-19 immunisation. The patients medical history included asthma, spinal cord injury and vascular history. Concomitant medications included 1000 mg vitamin C (MANUFACTURER UNKNOWN), 500 mg calcium (MANUFACTURER UNKNOWN), 1000 international unit (IU) vitamin D3 (MANUFACTURER UNKNOWN). All the concomitant medications were taken for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL9264) via an unspecified route of administration on 26Jan2021 at 16:00, as a single dose for COVID-19 immunisation. The patient was allergic to sulfa, naproxen sodium, shell fish and soy.  The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient had not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. The patient experienced heart palpations on 21Feb2021, started about 5 days after the 2nd dose, lasted about 2 to 3 days. No therapeutic measures were taken as a result of adverse events. The clinical outcome of heart palpitations was recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Chills, Dizziness, Dyspnoea, Fatigue
Clinical narrative: tiredness; injection site pain; Difficulty breathing; swelling of throat (feels that way),; Dizziness; weakness; feeling unwell; nausea; fever; chills; headache; This is a spontaneous report received from a contactable consumer, the patient. A 63-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8727) via an unspecified route of administration in the left arm on 19Mar2021 at 14:00 as a single dose (at the age of 63-years-old) for COVID-19 immunisation. The medical history included type 2 diabetes. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), metformin (MANUFACTURER UNKNOWN) and levothyroxine (SYNTHROID) all for an unknown indication from an unknown . The patient did not receive any other vaccine within 4 weeks prior to the COVID vaccine. On 19Mar2021 at 21:30, the patient experienced difficulty breathing, swelling of throat (feels that way), dizziness, weakness, feeling unwell, nausea, fever, chills, headache, tiredness and injection site pain (vaccination site pain). The patient did not receive any treatment for the events. The clinical outcome of the events difficulty breathing, swelling of throat, dizziness, weakness, feeling unwell, nausea, fever, chills, headache, tiredness and injection site pain (vaccination site pain) were not recovered.   No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Headache, Malaise, Nausea, Pharyngeal swelling, Pyrexia
Clinical narrative: tiredness; injection site pain; Difficulty breathing; swelling of throat (feels that way),; Dizziness; weakness; feeling unwell; nausea; fever; chills; headache; This is a spontaneous report received from a contactable consumer, the patient. A 63-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8727) via an unspecified route of administration in the left arm on 19Mar2021 at 14:00 as a single dose (at the age of 63-years-old) for COVID-19 immunisation. The medical history included type 2 diabetes. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), metformin (MANUFACTURER UNKNOWN) and levothyroxine (SYNTHROID) all for an unknown indication from an unknown . The patient did not receive any other vaccine within 4 weeks prior to the COVID vaccine. On 19Mar2021 at 21:30, the patient experienced difficulty breathing, swelling of throat (feels that way), dizziness, weakness, feeling unwell, nausea, fever, chills, headache, tiredness and injection site pain (vaccination site pain). The patient did not receive any treatment for the events. The clinical outcome of the events difficulty breathing, swelling of throat, dizziness, weakness, feeling unwell, nausea, fever, chills, headache, tiredness and injection site pain (vaccination site pain) were not recovered.   No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: tiredness; injection site pain; Difficulty breathing; swelling of throat (feels that way),; Dizziness; weakness; feeling unwell; nausea; fever; chills; headache; This is a spontaneous report received from a contactable consumer, the patient. A 63-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8727) via an unspecified route of administration in the left arm on 19Mar2021 at 14:00 as a single dose (at the age of 63-years-old) for COVID-19 immunisation. The medical history included type 2 diabetes. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), metformin (MANUFACTURER UNKNOWN) and levothyroxine (SYNTHROID) all for an unknown indication from an unknown . The patient did not receive any other vaccine within 4 weeks prior to the COVID vaccine. On 19Mar2021 at 21:30, the patient experienced difficulty breathing, swelling of throat (feels that way), dizziness, weakness, feeling unwell, nausea, fever, chills, headache, tiredness and injection site pain (vaccination site pain). The patient did not receive any treatment for the events. The clinical outcome of the events difficulty breathing, swelling of throat, dizziness, weakness, feeling unwell, nausea, fever, chills, headache, tiredness and injection site pain (vaccination site pain) were not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Pyrexia
Clinical narrative: Chills; Fever 100.1degrees F; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 17Mar2021 at 10:00 (at the age of 71 years) as a single dose for COVID-19 immunisation. Medical history included multiple strokes, multiple sclerosis, breast and lung cancer and allergy (unspecified) on unknown dates. The patient received other medications within 2 weeks of vaccination (not reported as it was too many to get it listed). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration, on 24Feb2021 at 10:00 in the left arm as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 12:15, the patient experienced chills commencing 62 hours after second dose followed by fever. Therapeutic measures taken as a result of reported events included 2 Tylenol of 500 mg capsules. The clinical outcome of chills and fever were recovered on an unknown date in 2021.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Facial pain, Fatigue, Headache, Hypertension
Clinical narrative: Low back pain; Headache; Hypertension; Fatigue; Thirst; Numbness on the left side of face.; Pain on the left side of face.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration in the left arm on 12Mar2021 at 11:30 AM (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient did not have any allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 12Mar2021, after four hours post vaccination, the patient experienced headache, hypertension, fatigue and thirst. On 3rd day (15Mar2021) post vaccination, the patient experienced low back pain and one-week later the patient experienced numbness and pain on the left side of face. The patient took advil and voltaren gel as the treatment of events. The clinical outcome of the event headache, hypertension, fatigue, thirst was recovered with sequalae on 14Mar2021 and the outcome of low back pain, numbness on the left side of face and pain on the left side of face was recovered with sequalae.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Thirst
Clinical narrative: Low back pain; Headache; Hypertension; Fatigue; Thirst; Numbness on the left side of face.; Pain on the left side of face.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration in the left arm on 12Mar2021 at 11:30 AM (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient did not have any allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 12Mar2021, after four hours post vaccination, the patient experienced headache, hypertension, fatigue and thirst. On 3rd day (15Mar2021) post vaccination, the patient experienced low back pain and one-week later the patient experienced numbness and pain on the left side of face. The patient took advil and voltaren gel as the treatment of events. The clinical outcome of the event headache, hypertension, fatigue, thirst was recovered with sequalae on 14Mar2021 and the outcome of low back pain, numbness on the left side of face and pain on the left side of face was recovered with sequalae.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Urticaria
Clinical narrative: itching; mild rash; 5-6 hives; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 11Mar2021 at 10:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included osteoporosis and cystitis interstitial. The patient was not allergic to medications, food, or other products. Concomitant medications received within two weeks of vaccination included Citracal and vitamin D (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 19Mar2021 at 18:00, one week after the vaccination, the patient developed itching, mild rash and 5-6 hives. It was reported that the rash and itching were better and the hives were the same. The patient did not receive any treatment for these events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events itching and mild rash was recovering. The outcome of the event hives was not recovered at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dizziness, Hot flush
Clinical narrative: Dizziness; Hot flashes; Diarrhea; This is a spontaneous report received from a consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EH6208), via an unspecified route administration in the left arm on 19Mar2021 at 10:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfa allergy. Concomitant medication included TYLENOL for an unknown indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Mar2021 at 10:30, the patient experienced dizziness, hot flashes and diarrhea (after two hours of vaccine administration and lasted for several hours). The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events dizziness, hot flashes and diarrhea was resolved on an unspecified date in Mar2021.  No follow-up attempts are needed. No further information was expected.